Seeking Alpha

Merck (MRK) will continue recording sales and profits from acid reflux drugs Nexium and Prilosec...

Merck (MRK) will continue recording sales and profits from acid reflux drugs Nexium and Prilosec for at least another two years after AstraZenica (AZN) agreed not to exercise an option this year to acquire Merck's remaining interest in a partnership connected to the treatments. Merck expects the deal to add $200M to revenue and $0.03-$0.05 in EPS in 2012. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs